secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-06-10T20:21:05+00:00
Accession:  0001193125-26-265879
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics stockholders approve 24x increase in authorized shares to 300M
--------------------------------------------------------------------------------

- Authorized common shares increased from 12.5M to 300M via charter amendment effective June 10.
- Approved 2026 Equity Incentive Plan with initial reserve of 2,671,981 shares plus annual 5% escalator through 2036.
- Approved 2026 Employee Stock Purchase Plan with initial reserve of 267,198 shares.
- Approved issuance of common stock upon conversion of Series B Convertible Preferred, triggering change of control and >20% issuance.
- Stockholders elected directors Bob Holmen and Kristian Humer and ratified Deloitte as auditor for FY2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526265879/0001193125-26-265879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526265879/d142513d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer